Equitable Trust’s Biogen BIIB Stock Holding History

Equitable Trust’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,907	Closed	-$574K	–	271
2018 Q4	$574K	Sell	1,907 -367	-16%	-$117K	0.08%	173
2018 Q3	$804K	Sell	2,274 -653	-22%	-$225K	0.09%	165
2018 Q2	$849K	Buy	+2,927	New	+$823K	0.11%	152

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Equitable Trust's BIIB Position: Q1 2019 in Review

Equitable Trust sold out of Biogen (BIIB) in Q1 2019, closing a stake of 1,907 shares — an estimated $574K sold.

Equitable Trust first reported a position in BIIB in Q2 2018 and held it in 3 quarters. The position peaked at $849K in Q2 2018. 1,084 funds tracked by Wall St. Rank hold BIIB as of Q1 2019.

Equitable Trust reported no remaining Biogen position as of Q1 2019 after selling out during the quarter.
Equitable Trust sold 1,907 Biogen shares in Q1 2019, an estimated $574K.
Equitable Trust first reported a position in Biogen in Q2 2018 and held it in 3 quarters.
Equitable Trust's Biogen position peaked at $849K in Q2 2018.
1,084 funds tracked by Wall St. Rank held Biogen as of Q1 2019.

Based on Equitable Trust's 13F filing for Q1 2019, filed 15 May 2019.